The Challenges of Developing Drugs for NASH Cirrhosis: The Example of Belapectin

Time: 2:00 pm
day: Day 1 Stream 1 PM


  • Addressing cirrhosis in patients with clinical signs of portal hypertension
  • Interrogating therapeutic efficacy and expanding the scope of target patient populations
  • Innovating clinical trial design with adaptive design to determine dose and better understand efficacy